Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03386487 · ClinicalTrials.gov registry record · Phase 2
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
NCT03386487 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 228 participants.
The verdict
NCT03386487, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
Study Summary
A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)
Interventions
- DRUG Placebo Oral Tablet
- DRUG PF 04457845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2022-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03386487
The ClinicalTrials.gov registry entry for NCT03386487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03386487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03386487 about?
NCT03386487 is a clinical study titled "Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)". A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)
What is the current status of trial NCT03386487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2019-01-14. Estimated completion is 2022-07-25.
What interventions are being tested in trial NCT03386487?
The interventions under investigation include: Placebo Oral Tablet (DRUG), PF 04457845 (DRUG).
Who is sponsoring clinical trial NCT03386487?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.